Principles of personalized medicine and modern pharmaceutical technologies to optimize levodopa therapy of Parkinson's disease
Levodopa (3-hydroxy-L-tyrosine, the levorotatory isomerof 3,4-dihydroxyphenylalanine) is a biological precursor of the neurotransmitter dopamine and has been the "gold standard" in the treatment of Parkinsons disease for over 50 years. The widespread use of levodopa in clinical practice ha...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Research Center of Neurology
2021-06-01
|
| Series: | Анналы клинической и экспериментальной неврологии |
| Subjects: | |
| Online Access: | https://annaly-nevrologii.com/journal/pathID/article/viewFile/749/580 |
| _version_ | 1811244241717821440 |
|---|---|
| author | Denis А. Abaimov Ekaterina Yu. Fedotova Vsevolod V. Poleshchuk Maksim N. Andreev Oxana P. Trifonova Petr G. Lokhov Sergey N. Illarioshkin |
| author_facet | Denis А. Abaimov Ekaterina Yu. Fedotova Vsevolod V. Poleshchuk Maksim N. Andreev Oxana P. Trifonova Petr G. Lokhov Sergey N. Illarioshkin |
| author_sort | Denis А. Abaimov |
| collection | DOAJ |
| description | Levodopa (3-hydroxy-L-tyrosine, the levorotatory isomerof 3,4-dihydroxyphenylalanine) is a biological precursor of the neurotransmitter dopamine and has been the "gold standard" in the treatment of Parkinsons disease for over 50 years. The widespread use of levodopa in clinical practice has not only provided neurologists with unique data from many years of symptomatic replacement therapy for a severe neurodegenerative disease but has also clearly identified several serious problems associated with levodopa absorption and metabolism. This article discusses the modern approaches to personalized medicine, which aim to overcome the numerous difficulties in managing patients with Parkinsons disease and long-term levodopa use. A major focus is the review of strategies for selecting the optimal levodopa dosage regimen in specific patients and the main innovative dosage forms of this drug that improve its pharmacokinetics. |
| first_indexed | 2024-04-12T14:22:32Z |
| format | Article |
| id | doaj.art-efa13993ca984b48ba257cb62d3d1031 |
| institution | Directory Open Access Journal |
| issn | 2075-5473 2409-2533 |
| language | English |
| last_indexed | 2024-04-12T14:22:32Z |
| publishDate | 2021-06-01 |
| publisher | Research Center of Neurology |
| record_format | Article |
| series | Анналы клинической и экспериментальной неврологии |
| spelling | doaj.art-efa13993ca984b48ba257cb62d3d10312022-12-22T03:29:33ZengResearch Center of NeurologyАнналы клинической и экспериментальной неврологии2075-54732409-25332021-06-01152738210.25692/ACEN.2021.2.9554Principles of personalized medicine and modern pharmaceutical technologies to optimize levodopa therapy of Parkinson's diseaseDenis А. Abaimov0Ekaterina Yu. Fedotova1Vsevolod V. Poleshchuk2Maksim N. Andreev3Oxana P. Trifonova4Petr G. Lokhov5Sergey N. Illarioshkin6Research Center of NeurologyResearch Center of NeurologyResearch Center of Neurology,Research Center of NeurologyInstitute of Biomedical ChemistryInstitute of Biomedical ChemistryResearch Center of NeurologyLevodopa (3-hydroxy-L-tyrosine, the levorotatory isomerof 3,4-dihydroxyphenylalanine) is a biological precursor of the neurotransmitter dopamine and has been the "gold standard" in the treatment of Parkinsons disease for over 50 years. The widespread use of levodopa in clinical practice has not only provided neurologists with unique data from many years of symptomatic replacement therapy for a severe neurodegenerative disease but has also clearly identified several serious problems associated with levodopa absorption and metabolism. This article discusses the modern approaches to personalized medicine, which aim to overcome the numerous difficulties in managing patients with Parkinsons disease and long-term levodopa use. A major focus is the review of strategies for selecting the optimal levodopa dosage regimen in specific patients and the main innovative dosage forms of this drug that improve its pharmacokinetics.https://annaly-nevrologii.com/journal/pathID/article/viewFile/749/580parkinson's diseaselevodopadyskinesiamotor fluctuationspharmacokineticstherapeutic drug monitoring |
| spellingShingle | Denis А. Abaimov Ekaterina Yu. Fedotova Vsevolod V. Poleshchuk Maksim N. Andreev Oxana P. Trifonova Petr G. Lokhov Sergey N. Illarioshkin Principles of personalized medicine and modern pharmaceutical technologies to optimize levodopa therapy of Parkinson's disease Анналы клинической и экспериментальной неврологии parkinson's disease levodopa dyskinesia motor fluctuations pharmacokinetics therapeutic drug monitoring |
| title | Principles of personalized medicine and modern pharmaceutical technologies to optimize levodopa therapy of Parkinson's disease |
| title_full | Principles of personalized medicine and modern pharmaceutical technologies to optimize levodopa therapy of Parkinson's disease |
| title_fullStr | Principles of personalized medicine and modern pharmaceutical technologies to optimize levodopa therapy of Parkinson's disease |
| title_full_unstemmed | Principles of personalized medicine and modern pharmaceutical technologies to optimize levodopa therapy of Parkinson's disease |
| title_short | Principles of personalized medicine and modern pharmaceutical technologies to optimize levodopa therapy of Parkinson's disease |
| title_sort | principles of personalized medicine and modern pharmaceutical technologies to optimize levodopa therapy of parkinson s disease |
| topic | parkinson's disease levodopa dyskinesia motor fluctuations pharmacokinetics therapeutic drug monitoring |
| url | https://annaly-nevrologii.com/journal/pathID/article/viewFile/749/580 |
| work_keys_str_mv | AT denisaabaimov principlesofpersonalizedmedicineandmodernpharmaceuticaltechnologiestooptimizelevodopatherapyofparkinsonsdisease AT ekaterinayufedotova principlesofpersonalizedmedicineandmodernpharmaceuticaltechnologiestooptimizelevodopatherapyofparkinsonsdisease AT vsevolodvpoleshchuk principlesofpersonalizedmedicineandmodernpharmaceuticaltechnologiestooptimizelevodopatherapyofparkinsonsdisease AT maksimnandreev principlesofpersonalizedmedicineandmodernpharmaceuticaltechnologiestooptimizelevodopatherapyofparkinsonsdisease AT oxanaptrifonova principlesofpersonalizedmedicineandmodernpharmaceuticaltechnologiestooptimizelevodopatherapyofparkinsonsdisease AT petrglokhov principlesofpersonalizedmedicineandmodernpharmaceuticaltechnologiestooptimizelevodopatherapyofparkinsonsdisease AT sergeynillarioshkin principlesofpersonalizedmedicineandmodernpharmaceuticaltechnologiestooptimizelevodopatherapyofparkinsonsdisease |